Skip to content
    ACHC
    Earnings call· Jun 2026(Q2 FY26)

    Acadia Healthcare Company Q2 FY26 earnings call ACHC

    Jul 29, 2026 Source

    Executive summary

    Acadia Healthcare Q2 FY26 — Solid Performance Driven by Operational Execution and New Facility Ramps

    Acadia Healthcare delivered solid Q2 FY26 results, exceeding revenue guidance and achieving adjusted EBITDA and EPS near the high end of expectations, driven by strong operational execution and successful ramp-up of new facilities. The company generated significant free cash flow, reduced debt, and remains focused on disciplined capital deployment and optimizing its existing capacity. While facing some headwinds from Medicaid program changes and a PLGL reserve adjustment, management expressed confidence in achieving its long-term incremental EBITDA targets from new beds and expects continued operational performance in the coming quarters.

    Highlights

    5
    • Total revenue of $866 million was above the high end of guidance, with normalized growth of 2.8% year-over-year.

    • Generated $124 million of free cash flow and reduced debt by $113 million, leading to a net leverage ratio of 4.1x adjusted EBITDA.

    • New facilities (2023-2026 cohorts) are ramping ahead of expectations, contributing positive adjusted EBITDA and remaining on track for $200 million incremental adjusted EBITDA relative to 2025.

    • Opened two new acute facilities on schedule, adding over 300 beds in H1 FY26, with plans to add 500-600 beds in total for FY26.

    • Stable and positive labor environment with ~3% year-over-year wage cost growth and improved recruiting/retention.

    Concerns

    3
    • Adjusted EBITDA of $149.2 million was negatively impacted by $2.5 million due to a $28.6 million increase in professional and general liability reserves, partially offset by a $26.1 million Florida supplemental payment benefit.

    • Same-facility revenue growth was impacted by approximately 1% from changes in the New York Medicaid program on Pennsylvania facilities.

    • CTC service line revenue was flat year-over-year despite adding 6 new centers, performing slightly behind expectations.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year Capital Expenditures
    $235 million to $255 million
    medium materiality
    High
    Full-year Revenue
    $3.4 billion to $3.45 billion
    high materiality
    High
    Full-year Adjusted EBITDA
    $590 million to $615 million
    high materiality
    High
    Full-year Adjusted EPS
    $1.45 to $1.60
    high materiality
    High
    Full-year Operating Cash Flow
    $350 million to $400 million
    medium materiality
    High
    Incremental Adjusted EBITDA from Supplemental Payment Programs
    more than $20 million
    medium materiality
    Medium
    Start-up Losses
    $12 million to $14 million
    low materiality
    High
    Start-up Losses
    below $12 million
    low materiality
    High

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Total Company
    Total revenue was flat year-over-year, but showed 2.8% growth after normalizing for supplemental payments. Same-facility revenue was flat, with patient day growth offset by a decrease in revenue per patient day, also impacted by NY Medicaid changes.
    Normalized total revenue growth: 2.8% YoYSame-facility revenue growth: 3.2% YoY (normalized)Same-facility patient days: +0.8% YoYRevenue per patient day: -0.8% YoYSame-facility adjusted EBITDA: $200.9M
    $866Mflat
    Acute business
    Revenue was flat year-over-year, but reflects 6% growth after normalizing for supplemental payments. Delivered strong volume and admissions growth from existing and new facilities.
    Normalized growth: 6% YoY
    $495Mflat
    Specialty business
    Delivered solid performance with a sequential increase in revenue. Experienced a full quarter impact from the New York Medicaid decision, with the team working to expand referral sources.
    $134M4% sequential increase
    RTC service line
    Delivered strong revenue growth driven by solid volume growth and capacity expansions completed last year.
    Solid volume growthGrowth in revenue per day
    $97M12%
    CTC business
    Revenue was flat year-over-year and performed slightly behind expectations. Demand for services remains steady, and the team is focused on meeting patient needs and improving performance.
    $141Mflat

    Operational metrics

    15
    Debt Repaid
    $113M
    Q2 FY26

    Amount of debt repaid during the second quarter.

    Cash and Cash Equivalents
    $171M
    as of June 30, 2026

    Balance at the end of the second quarter.

    Start-up Losses
    $12M
    Q2 FY26

    Losses from facilities opening in the last 12 months, better than expectations.

    Corporate Overhead Cost Decline
    $3MQoQ decline
    Q2 FY26

    Compared with the first quarter, corporate overhead costs declined.

    AR Days
    49%declined vs Q1
    end of Q2 FY26

    Days sales outstanding declined compared to the first quarter.

    Wage Cost Growth
    ~3%
    YoY

    Overall stable year-over-year wage cost growth.

    New Beds Added
    >300
    H1 FY26

    Total beds added in the first half of the year.

    Planned Beds for FY26
    500-600
    FY26

    Total planned bed additions for the full year 2026.

    Incremental Adjusted EBITDA from New Facilities
    $200M
    relative to 2025

    Target for incremental adjusted EBITDA from 2023-2026 cohorts of new facilities.

    Professional and General Liability Reserves Adjustment
    $28.6M
    Q2 FY26

    Increase in reserves primarily driven by progress in moving towards settlement related to certain prior year cases.

    Professional and General Liability Reserves Forecast (Current Year)
    $100M-$110M
    FY26

    Expected cost for 2026, unchanged by mid-year actuarial review.

    Professional and General Liability Reserves (Current Year with adjustment)
    ~$135M
    FY26

    Total trending for the current year including the prior year adjustment.

    Florida Supplemental Payment Benefit
    $26.1M
    Q2 FY26

    Benefit from Florida supplemental payments related to the 2025 program year.

    NY Medicaid Program Impact
    ~1%
    Q2 FY26

    Impact from changes in the New York Medicaid program on Pennsylvania facilities.

    Measurement-Based Care Initiative
    ongoing

    Expanding to additional acute facilities, specialty, and CTC service lines, leveraging evidence-based practices and real-time data to guide clinical decision-making and improve treatment outcomes.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trends0.8%%
    Same facility volumes0.8%%
    Payer mix supplemental payments$22.3MUSD
    Adjusted EPS EBITDA leverage guidanceAdjusted EBITDA $149.2M; Net leverage ratio 4.1x; FY26 Adjusted EBITDA $590M-$615M; FY26 Adjusted EPS $1.45-$1.60USD

    Deals & partnerships

    3
    Orlando HealthOpened a new 144-bed JV acute facility

    New 144-bed JV facility opened in Florida on schedule during Q2 FY26.

    Methodist Jennie EdmundsonOpened a new 96-bed JV acute facility

    New 96-bed JV facility opened in Iowa on schedule during Q2 FY26.

    Premier Health SystemsPartnership for opening new acute facilities

    Successfully opened 2 new acute facilities in June in partnership with Premier Health Systems (likely referring to the Orlando Health and Methodist Jennie Edmundson JVs).

    Risks & headwinds

    4
    Professional and General Liability (PLGL) Reserves IncreaseQ2 FY26 (for prior years)

    $28.6 million increase in reserves; $2.5 million negative impact on Q2 adjusted EBITDA

    Mitigation: Proactive mid-year actuarial reviews; strong risk management programs; aggressive defense and strategic management of claims; current year (2026) forecast remains stable.

    New York Medicaid Program ChangesQ2 FY26 (full quarter impact)

    ~1% impact on same-facility revenue growth

    Mitigation: Team working to build upon and expand referral sources within Pennsylvania and in additional states.

    CTC Service Line UnderperformanceQ2 FY26

    Revenue flat year-over-year

    Mitigation: Focused on patient/client experience; evaluating marketing deployment; ensuring clinics are first choice in their regions.

    Payer Pushback/TensionOngoing

    Ongoing 'push and pull' with payers; low to mid-single digit rate increases

    Mitigation: Maintaining strong relationships; advocating for patients; documenting acuity; sharing outcomes; collaborative approach; ensuring patients receive right care in right setting.

    What to watch in Q3 FY26

    5

    Start-up losses trajectory

    Q3 FY26, Q4 FY26
    Current$12 million in Q2 FY26
    Target$12 million to $14 million in Q3 FY26, then below $12 million in Q4 FY26

    Why it matters

    Indicates the pace of new facility ramp-ups and their contribution to overall profitability, reflecting management's operational execution.

    With respect to the start-up losses, we have had 2 quarters in a row where our losses for the facilities opening in the last 12 months has been around $12 million. Those facilities are doing a great job in the early stages of opening and are ahead of our expectations. And we revised our full year expectation there slightly and would guide everyone towards a little bit of a step-up in that $12 million as we think about the third quarter, just given 2 new facilities at the end of the second quarter as well as one more facility opening in the third quarter. So I think it could get a little bit larger, not significantly, but maybe in the $12 million to $14 million range before we really have an opportunity starting in the fourth quarter to see that number come back down certainly below the $12 million as we think about what's possible for the fourth quarter based on progress that we've made so far with those new facilities.

    Q&A highlights

    10

    Can you provide more qualitative comments on the progress and achievability of the $200 million incremental adjusted EBITDA target from the 2023-2026 new bed cohorts?

    Management expressed high confidence in achieving the $200 million target, noting that revenue, volume, and facility-level EBITDA for these cohorts are ahead of expectations. They cited the Coachella Valley facility (2024 de novo) as an example, which is now over 90% occupancy and planning for additional beds, demonstrating successful ramp-up.

    We have confidence in delivering on the $200 million of the incremental adjusted EBITDA. It's been a significant focus for the team. I think we've made further progress during the second quarter with really revenue volume, facility level EBITDA. They were ahead of our expectations for each cohort.

    asked by Brian Tanquilut · answered by Debra Osteen

    3 min read7 chapters

    Detailed Narrative

    01

    Operational Execution and New Facility Ramps

    Acadia has made significant advances in operational execution, with new facilities from the 2023-2026 cohorts ramping ahead of expectations in terms of revenue, volume, and facility-level EBITDA. This success is attributed to a heightened sense of urgency, accelerated timelines for licensing, accreditation, and payer contracting, disciplined expense control, and strong referral partnerships. The Coachella Valley facility, a 2024 de novo, is now above 90% occupancy, leading to plans for additional bed capacity.

    02

    Financial Performance and Capital Deployment

    The company delivered Q2 FY26 revenue above the high end of guidance, and adjusted EBITDA and adjusted EPS near the high end. Strong free cash flow of $124 million was generated, contributing to a $113 million reduction in debt and a net leverage ratio of 4.1x adjusted EBITDA. Management is taking a disciplined approach to capital deployment, including CapEx, and expects continued positive free cash flow in the second half of the year.

    03

    Service Line Performance

    The Acute business saw continued progress in ramping occupancy and revenue at new facilities, with 6% growth after normalizing for supplemental payments. The Specialty business delivered solid performance with a $5 million sequential revenue increase, mitigating some impact from New York Medicaid changes. The RTC service line showed strong 12% year-over-year revenue growth driven by volume and capacity expansions. The CTC service line's revenue was flat year-over-year, performing slightly behind expectations despite opening two new clinics.

    04

    Labor and Staffing Environment

    Acadia continues to experience a stable and positive labor environment, with strong recruiting and retention of employees. The company has successfully staffed new facilities, including bringing on new leadership teams. Wage cost growth has been trending around 3% year-over-year. The partnership model with JVs provides an advantage by allowing staff from partner units/hospitals to transition to new facilities.

    05

    Revenue Cycle Management Progress

    The company reported stability in bad debt and denials sequentially from Q1 to Q2, with a year-over-year improvement in the headwind from $9 million to $7 million. This progress is driven by a three-pronged approach: strengthening processes with revenue cycle leaders, leveraging technology for proactive intervention, and a strategic appeals process to learn from and apply across markets.

    06

    Professional and General Liability (PLGL) Reserves

    Acadia made a proactive decision to conduct mid-year actuarial reviews in 2026. A $28.6 million adjustment was made to increase PLGL reserves in Q2, primarily driven by progress in settling certain prior-year cases from the 2025 policy year. While this adjustment impacted Q2 adjusted EBITDA, the forecast for current year (2026) reserves remains in line with expectations at $100 million to $110 million, with the total for the year now trending around $135 million including the prior-year adjustment.

    07

    Medicaid Work Requirements Impact

    Management believes that new Medicaid work requirements, set to be implemented in January for states with expanded Medicaid, will not have a material impact on Acadia. The company anticipates that its patients, particularly those with severe mental illness and substance use disorders, will qualify for the exemptions laid out in the requirements, which were thoughtfully designed to cover such populations.

    AI-generated summary of the company’s earnings call. Not investment advice.